Kindeva Drug Delivery and Orbia Fluor & Energy Materials Announce Collaboration for Low GWP Propellant Conversion

Press Release

Sustainability

5 December 2023

WOODBURY, Minn. and St. LOUIS, Mo. and BOSTON; Dec. 5, 2023 (Business Wire) – Kindeva Drug Delivery (Kindeva), a leading global contract development and manufacturing organization (CDMO) focused on drug-device combination products, and Orbia Advance Corporation, S.A.B. de C.V. (BMV: ORBIA*) Orbia Fluor & Energy Materials, a global leader in the development, manufacture, and supply of fluoroproducts and technologies, announced today a co-development collaboration for the conversion from existing marketed pressurised Metered Dose Inhaler (pMDI) products to Orbia Fluor & Energy Materials more sustainable and environmentally-conscious medical propellant; HFA 152a, known as Zephex® 152a.

This strategic collaboration will focus on accelerating the conversion of existing marketed pMDI inhaler products to low global warming potential (GWP) pMDIs utilizing Orbia Fluor & Energy Materials Zephex 152a platform with the objective of reducing respiratory healthcare carbon emissions while safeguarding patient choice. This partnership aims to facilitate conversion of pMDI products to the lower GWP propellent 152a and progressing them through clinical development.

The converted pMDI products will be available for licensing with anticipated launches occurring in-line with the expected commencement of a phase-down of existing pMDI systems containing HFC-134a and HFC-227ea within the European Union.

Orbia Fluor & Energy Materials President Gregg Smith said, “This is a significant step forward in bringing our lower GWP medical propellant Zephex 152a to the market and we are excited to partner with Kindeva to ensure patients have access to this life saving technology.”

David Stevens, Global Chief Commercial Officer of Kindeva said, “We are proud to partner with Orbia Fluor & Energy Materials to help achieve the dual objectives of significantly reducing the environmental impact of pMDI inhalers and ensuring patient access to inhaler options is not compromised.”

Stevens continued, “Kindeva has a rich history of innovation in the pMDI market and our comprehensive development and manufacturing capabilities uniquely enable us to help lead this transition. This strategic collaboration is symbolic of not only the commitment both partners have for advancing sustainability and advocating for patient choice, but also of the shared values of the two organizations.”

Orbia Fluor & Energy Materials and Kindeva are both exhibiting at the Drug Delivery to the Lungs conference (DDL) in Edinburgh, U.K., December 6-8 (booth #146 and #147, respectively) where they will be speaking with industry leaders on the low GWP propellent, 152a, and further relevant topics.

About Kindeva Drug Delivery

Kindeva is a global contract development manufacturing organization focused on drug-device combination products. Kindeva develops and manufactures products across a broad range of complex drug-delivery formats, including injectables (autoinjector, intradermal, microneedle), pulmonary and nasal, and transdermal patches. Its service offering spans early-stage feasibility through commercial scale drug product fill-finish, container closure system manufacturing, and drug-device product assembly. Kindeva serves a global client base from its nine manufacturing and research and development facilities located in the U.S. and U.K. For more information, please visit www.kindevadd.com.

VIEW ALL ARTICLES